MannKind (MNKD) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oric Pharmaceuticals (ORIC) has outperformed MannKind (MNKD) over the past year, losing 14.9% versus a loss of 38.9%. Over five years, ORIC leads with a -26.0% price change compared with -32.2% for MNKD. Oric Pharmaceuticals is the larger company by market cap ($1.25 billion vs $1.10 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNKD | ORIC |
|---|---|---|
| Share price | $3.42 | $12.03 |
| Market cap | $1.10B | $1.25B |
| 1-day change | -0.87% | +0.17% |
| YTD return | -39.15% | +46.82% |
| 1-year return | -38.94% | -14.94% |
| 5-year return | -32.22% | -26.00% |
| Forward P/E | 26.82 | — |
| EPS (TTM) | $-0.14 | $-1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.51 | $14.68 |
| 52-week low | $2.23 | $7.23 |
| Distance from 52-week high | -47.47% | -18.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +129.24% | +78.14% |
| Average volume | 4.48M | 1.45M |
| Shares outstanding | 321.54M | 103.65M |
| Employees | 591 | 111 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORIC has outperformed MNKD by 24.0 percentage points over the past year.
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
MNKD vs ORIC FAQ
Which is bigger, MannKind or Oric Pharmaceuticals?
Oric Pharmaceuticals (ORIC) is larger, with a market capitalization of $1.25B compared with $1.10B for MannKind (MNKD).
Which stock has performed better over the past year, MNKD or ORIC?
ORIC returned -14.94% over the past 12 months, compared with -38.94% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are MannKind and Oric Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.